JP2025502147A5 - - Google Patents

Info

Publication number
JP2025502147A5
JP2025502147A5 JP2024541604A JP2024541604A JP2025502147A5 JP 2025502147 A5 JP2025502147 A5 JP 2025502147A5 JP 2024541604 A JP2024541604 A JP 2024541604A JP 2024541604 A JP2024541604 A JP 2024541604A JP 2025502147 A5 JP2025502147 A5 JP 2025502147A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
compound according
group
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502147A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/010514 external-priority patent/WO2023137026A1/en
Publication of JP2025502147A publication Critical patent/JP2025502147A/ja
Publication of JP2025502147A5 publication Critical patent/JP2025502147A5/ja
Pending legal-status Critical Current

Links

JP2024541604A 2022-01-12 2023-01-10 タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用 Pending JP2025502147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263298786P 2022-01-12 2022-01-12
US63/298,786 2022-01-12
PCT/US2023/010514 WO2023137026A1 (en) 2022-01-12 2023-01-10 Camptothecin analogs conjugated to a glutamine residue in a protein, and their use

Publications (2)

Publication Number Publication Date
JP2025502147A JP2025502147A (ja) 2025-01-24
JP2025502147A5 true JP2025502147A5 (cg-RX-API-DMAC7.html) 2026-01-08

Family

ID=85222406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541604A Pending JP2025502147A (ja) 2022-01-12 2023-01-10 タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用

Country Status (9)

Country Link
US (1) US20230287138A1 (cg-RX-API-DMAC7.html)
EP (1) EP4463187A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025502147A (cg-RX-API-DMAC7.html)
KR (1) KR20240134010A (cg-RX-API-DMAC7.html)
CN (1) CN118829449A (cg-RX-API-DMAC7.html)
AU (1) AU2023207960A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241734A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008640A (cg-RX-API-DMAC7.html)
WO (1) WO2023137026A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605459B2 (en) 2020-07-13 2026-04-21 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
KR20250004952A (ko) * 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체
WO2024138000A1 (en) * 2022-12-21 2024-06-27 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2024168199A1 (en) * 2023-02-09 2024-08-15 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates via inverse electron demand diels-alder reactions
EP4720075A1 (en) * 2023-05-26 2026-04-08 NJ Bio, Inc. Topoisomerase inhibitors, methods of making, and methods of use thereof
WO2025042953A1 (en) * 2023-08-22 2025-02-27 The Research Foundation For The State University Of New York Antibody-drug complexes with topoisomerase inhibitors
WO2025082990A1 (en) * 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
CN120053678A (zh) * 2023-11-30 2025-05-30 上海医药集团股份有限公司 一种高喜树碱类抗体偶联药物、其制备方法及应用
WO2025199666A1 (en) * 2024-03-25 2025-10-02 Canwell Biotech Limited Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof
WO2026013234A1 (en) * 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)
WO2026046398A1 (en) * 2024-08-30 2026-03-05 Hansoh Bio Llc Novel camptothecin derivative and conjugate thereof, preparation method therefor and application thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
CN100406460C (zh) 2003-11-10 2008-07-30 中国科学院上海药物研究所 喜树碱的新衍生物、制备方法和用途
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
CN1587265A (zh) 2004-07-08 2005-03-02 浙江大学 10-烷氧基喜树碱衍生物及其制备方法与应用
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
EP2601298B1 (en) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
TWI871999B (zh) * 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
WO2018026742A1 (en) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
CA3042428A1 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
EP3700577A1 (en) * 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
JP7328990B2 (ja) 2018-04-30 2023-08-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Her2及び/またはaplp2に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
WO2019217591A1 (en) * 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
EP3794042B1 (en) * 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
JP2022517767A (ja) 2019-01-08 2022-03-10 レゲネロン ファーマシューティカルス,インコーポレーテッド 無痕跡型リンカー及びそのタンパク質-コンジュゲート
EP3976112A1 (en) * 2019-06-03 2022-04-06 Synaffix B.V. Acetal-based cleavable linkers
CA3166619A1 (en) * 2020-02-28 2021-09-02 Julian Andreev Bispecific antigen binding molecules that bind her2, and methods of use thereof
US12605459B2 (en) * 2020-07-13 2026-04-21 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
US20250122282A2 (en) * 2020-09-04 2025-04-17 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
MX2023011630A (es) * 2021-03-30 2024-01-24 Mablink Bioscience Enlace autorreactivo activado por enzima que tiene propiedades fisicoquimicas y farmacologicas mejoradas.
AU2022269073A1 (en) * 2021-05-07 2023-11-23 ALX Oncology Inc. Exatecan derivatives and antibody-drug conjugates thereof
MX2023012920A (es) * 2021-06-02 2023-11-13 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Conjugado anticuerpo-farmaco y metodo de preparacion y uso del mismo.
EP4545096A1 (en) * 2022-06-27 2025-04-30 Trioar, Inc. Compound comprising self-immolative group and ligand-drug conjugate comprising same

Similar Documents

Publication Publication Date Title
JP2023534437A5 (cg-RX-API-DMAC7.html)
JP6908656B2 (ja) 薬物結合体のためのスルホンアミド含有連結系
TWI820044B (zh) 抗體-吡咯并苯二氮呯衍生物複合體
JP2023106627A (ja) Peg化薬物リンカー及びその中間体を調製するためのプロセス
JP7605290B2 (ja) 化合物またはその塩、およびそれらにより得られる抗体
CN117500527A (zh) 抗体药物偶联物及其制备方法和用途
JP2024509099A (ja) 抗her2抗体‐薬物コンジュゲートおよびその使用
TW200302227A (en) Geranyl group-containing compounds
JP2022540395A (ja) 細胞結合性分子-チューブリシン誘導体共役体及びその調製方法
JP7658450B2 (ja) 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
JP2025512735A5 (cg-RX-API-DMAC7.html)
JP2025111561A (ja) 化合物またはその塩、およびそれらにより得られる抗体
JP2025124732A (ja) 化合物またはその塩、およびそれらにより得られる抗体
WO2024210154A1 (ja) 抗体および機能性物質のコンジュゲート、抗体誘導体ならびに化合物、またはそれらの塩
JP2026048648A (ja) 癌を治療するための組み合わせ療法
TWI924207B (zh) 從生物活性化合物的偶聯物的選擇性藥物釋放
WO2010010912A1 (ja) BSHを導入した光学活性なα-アミノ酸類およびその合成方法
CN112996778A (zh) 制备微管溶素及其中间体的替代方法
WO2023054706A1 (ja) 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
WO2024024935A1 (ja) 抗腫瘍効果を有する抗体薬物複合体の新規製造方法
JP2024512046A5 (cg-RX-API-DMAC7.html)
WO2024235071A9 (en) Conjugate and the preparation thereof
KR20190143246A (ko) 신규한 링커 화합물 및 이를 포함하는 위치 특이적인 항체-약물 결합체 화합물
KR101597105B1 (ko) 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
CN118119639A (zh) 抗体和功能性物质的缀合物或其盐、以及其制造中使用的抗体衍生物和化合物或它们的盐